active
ACTIVE SINCE: 2021
Back to Collaborations

Bristol Myers Squibb Foundation: Pilot Study in Lung Cancer and Cutaneous Melanoma Management

This project aims to lower the percentage of patients abandoning treatment and increase the number of new diagnoses for lung cancer and cutaneous melanoma patients.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
PARTNERING WITH:
SEE ALL PARTNER ORGANIZATIONS
Pharma Company Foundation 1
Hospitals Health Facilities 1

BCH will implement a model for enhanced healthcare using tele-assistance tools with interventions aimed at reducing the impact of lung cancer and cutaneous melanoma for patients treated in the public health system. This project aims to lower the percentage of patients abandoning treatment and increase the number of new diagnoses.

Results and milestones
  • Reached 37,400 teleconsultations mark (with 27,900+ completed in 2022) and about 210 patients reached daily
  • Within a 4-month period, a total of 6,000 patients were reached for pre-CT/MRI evaluations
  • Achieved patient satisfaction rating of 92% net promoter score (NPS) so far
Geographic Reach
  • Americas
See Where
Disease Area
  • Non-communicable Diseases
See Disease Areas
SGDs the partnership contributes to
SDG 3: Good Health and Wellbeing
  1. 3.4: NCDs (including mental health)
  2. 3.8: Achieve universal health coverage
SDG 17: Partnerships for the Goals 
Partner organizations
Pharma Company Foundation

Bristol Myers Squibb Foundation

Hospitals Health Facilities

Fundação Pio XII – Barretos Cancer Hospital

Geographic Reach

Americas

  • Brazil

Disease Area

Non-communicable Diseases

  • Cancer
    • Lung Cancer
    • Melanoma